Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Atomic and Specificity Details of Mucin 1 O-Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling

  • Coelho, Helena
  • De las Rivas, Matilde
  • Grosso, Ana S.
  • Diniz, Ana
  • Soares, Cátia O.
  • Francisco, Rodrigo A.
  • Dias, Jorge S.
  • Compañón, Ismael
  • Sun, Lingbo
  • Narimatsu, Yoshiki
  • Vakhrushev, Sergey Y.
  • Clausen, Henrik
  • Cabrita, Eurico J.
  • Jiménez Barbero, Jesús
  • Corzana, Francisco
  • Hurtado Guerrero, Ramón
  • Marcelo, Filipa
[EN] The large family of polypeptide GalNAc-transferases (GalNAc-Ts) controls with precision how GalNAc O-glycans are added in the tandem repeat regions of mucins (e.g., MUC1). However, the structural features behind the creation of well-defined and clustered patterns of O-glycans in mucins are poorly understood. In this context, herein, we disclose the full process of MUC1 O-glycosylation by GalNAc-T2/T3/T4 isoforms by NMR spectroscopy assisted by molecular modeling protocols. By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue. In a glycosylated substrate, with yet multiple acceptor sites, the lectin domain contributes to orientate acceptor sites to the catalytic domain. Our experiments suggest that during this process, neighboring tandem repeats are critical for further glycosylation of acceptor sites by GalNAc-T2/T4 in a lectin-assisted manner. Our studies also show local conformational changes in the peptide backbone during incorporation of GalNAc residues, which might explain GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate. Interestingly, we postulate that a specific salt-bridge and the inverse gamma-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region. In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope. Finally, the NMR methodology established herein can be extended to other glycosyltransferases, such as C1GalT1 and ST6GalNAc-I, to determine the specificity toward complex mucin acceptor substrates., The authors acknowledge Fundação para a Ciência e a Tecnologia (FCT-Portugal) for funding the projects, IF/00780/2015, PTDC/BIA-MIB/31028/2017, and UCIBIO project (UIDP/04378/2020 and UIDB/04378/2020), and Associate Laboratory Institute for Health and Bioeconomy─i4HB project (LA/P/0140/2020). The authors also thank FCT-Portugal for the PhD grant attributed to ASG (SFRH/BD/140394/2018) and A.D. (PD/BD/142847/2018) under the PTNMRPhD Program (PD00065/2013) and for the Norma transitória DL 57/2016 Program Contract to J.S.D. The NMR spectrometers are part of the National NMR Facility supported by FCT-Portugal (ROTEIRO/0031/2013-PINFRA/22161/2016, cofinanced by FEDER through COMPETE 2020, POCI and PORL and FCT through PIDDAC). RHG thanks ARAID, the Spanish Ministry of Science, Innovation and Universities (BFU2016-75633-P and PID2019-105451GB-I00), and Gobierno de Aragón (E34_R17 and LMP58_18 to R.H-G.) with FEDER (2014–2020) funds for “Building Europe from Aragón” for the financial support. F.C. thanks Agencia Estatal Investigación (AEI, Spain) (grant RTI2018-099592-B-C21). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement no. 956544. J.J.-B. and H.C. thank EU for funding (Tollerant ITN, GA-642157). F.M. and J.J.-B. acknowledge the COST Action GLYCONanoProbes (CA18132). J.J.-B also thanks the European Research Council for the financial support (ERC-2017-AdG, project number 788143-RECGLYCANMR), AEI (Spain, grant RTI218-094751-B-C21), and CIBER, an initiative of Instituto de Salud Carlos III (ISCIII), Madrid, Spain. H.C. acknowledges the Lundbeck Foundation and the Danish National Research Foundation (DNRF107).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Detection of Tumor-Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes

  • Corzana, Francisco
  • Asín, Alicia
  • Eguskiza, Ander
  • De Tomi, Elisa
  • Martín-Carnicero, Alfonso
  • Martínez-Moral, María P.
  • Mangini, Vincenzo
  • Papi, Francesco
  • Bretón, Carmen
  • Oroz, Paula
  • Lagartera, Laura
  • Jiménez-Moreno, Ester
  • Avenoza, Alberto
  • Busto, Jesús H.
  • Nativi, Cristina
  • Asensio, Juan Luis
  • Hurtado-Guerrero, Ramón
  • Peregrina, Jesús M.
  • Malerba, Giovanni
  • Martínez, Alfredo
  • Fiammengo, Roberto
Pancreatic cancer is one of the deadliest cancers worldwide, mainly due to late diagnosis. Therefore, there is an urgent need for novel diagnostic approaches to identify the disease as early as possible. We have developed a diagnostic assay for pancreatic cancer based on the detection of naturally occurring tumor associated autoantibodies against Mucin-1 (MUC1) using engineered glycopeptides on nanoparticle probes. We used a structure-guided approach to develop unnatural glycopeptides as model antigens for tumor-associated MUC1. We designed a collection of 13 glycopeptides to bind either SM3 or 5E5, two monoclonal antibodies with distinct epitopes known to recognize tumor associated MUC1. Glycopeptide binding to SM3 or 5E5 was confirmed by surface plasmon resonance and rationalized by molecular dynamics simulations. These model antigens were conjugated to gold nanoparticles and used in a dot-blot assay to detect autoantibodies in serum samples from pancreatic cancer patients and healthy volunteers. Nanoparticle probes with glycopeptides displaying the SM3 epitope did not have diagnostic potential. Instead, nanoparticle probes displaying glycopeptides with high affinity for 5E5 could discriminate between cancer patients and healthy controls. Remarkably, the best-discriminating probes show significantly better true and false positive rates than the current clinical biomarkers CA19-9 and carcinoembryonic antigen (CEA)., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No956544. We thank Dr. Sara Gasperini of the General Pathology Section, Department of Medicine, University of Verona, for providing access and assistance with the LI–COR Odyssey Infrared Imaging System. We thank Prof.Henrik Clausen from Copenhagen Center for Glycomics atUniversity of Copenhagen for his insightful comments. F.C.thanks the Mizutani Foundation for Glycoscience (grant220115) and AECC (INNOVA 2023 project). A.A. and C.B.thank the Asociación Española Contra el Cáncer (AECC),sección La Rioja, for their doctoral fellow ships. We thank the ALBA (Barcelona, Spain) synchrotron beamline XA-LOC. We thank ARAID, the Agencia Estatal de Investiga-ción (AEI, BFU201675633-P, PID2019-105451GB-I00, and PID2022-136362NB-I00 to R.H.-G., PID2022-136735OB-I00to A.M., PID2021-127030OA-I00 to E.J.-M, PID2022-141085NB-100 to J.L.A, and PID2021-127622OB-I00 andPDC2022-133725-C21 to F.C. and J.H.B.), Universidad de La Rioja (REGI22/47 and REGI22/16), Gobierno de Aragón (E34_R17 and LMP58_18 to R.H.-G.) with FEDER(2014–2020) funds for “Building Europe from Aragón” forfinancial support, and the COST Action CA18103 INNO-GLY: Innovation with Glycans new frontiers from synthesis to new biological targets. CN thanks Fondazione AIRC,project IG25762. Open Access publishing facilitated byUniversità degli Studi di Verona, as part of the Wiley -CRUI-CARE agreement., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Turning universal O into rare Bombay type blood

  • Anso, Itxaso
  • Naegeli, Andreas
  • Cifuente, Javier O.
  • Orrantia, Ane
  • Andersson, Erica
  • Zenarruzabeitia, Olatz
  • Moraleda-Montoya, Alicia
  • García-Alija, Mikel
  • Corzana, Francisco
  • Orbe, Rafael A. Del
  • Borrego, Francisco
  • Trastoy, Beatriz
  • Sjögren, Jonathan
  • Guerin, Marcelo E.
Red blood cell antigens play critical roles in blood transfusion since donor incompatibilities can be lethal. Recipients with the rare total deficiency in H antigen, the Oh Bombay phenotype, can only be transfused with group Oh blood to avoid serious transfusion reactions. We discover FucOB from the mucin-degrading bacteria Akkermansia muciniphila as an α-1,2-fucosidase able to hydrolyze Type I, Type II, Type III and Type V H antigens to obtain the afucosylated Bombay phenotype in vitro. X-ray crystal structures of FucOB show a three-domain architecture, including a GH95 glycoside hydrolase. The structural data together with site-directed mutagenesis, enzymatic activity and computational methods provide molecular insights into substrate specificity and catalysis. Furthermore, using agglutination tests and flow cytometry-based techniques, we demonstrate the ability of FucOB to convert universal O type into rare Bombay type blood, providing exciting possibilities to facilitate transfusion in recipients/patients with Bombay phenotype., This work was supported by the MINECO/FEDER EU contract PID2019-105649RB-I00 and Severo Ochoa Excellence Accreditation SEV-2016-0644; the Basque Government contracts KK-2021-00034 and KK-2022/00107 and NIH R01AI149297 (to M.E.G.); EU Marie-Sklodowska Curie ITN, DIRNANO, contract 956544 and the Mizutani Foundation for Glycoscience contract 220115 (to F.C.). This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 844905 and “Ramón y Cajal” fellow from the Spanish Ministry of Economy and Competitiveness (B.T.) and the Basque Government (I.A.). We acknowledge Diamond Light Source (proposals mx28360), ALBA synchrotron beamline BL13-XALOC (mx2020094584), beamline X06DA at SLS (Villigen Switzerland; proposal 20201980), and iNEXT (proposals 1618/2538) for providing access to synchrotron radiation facilities., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploring photoredox catalytic reactions as an entry to glycosyl-α-amino acids

  • Bretón, Carmen
  • Oroz, Paula
  • Torres, Miguel
  • Zurbano, María M.
  • García-Orduña, Pilar
  • Avenoza, Alberto
  • Busto, Jesús H.
  • Corzana, Francisco
  • Peregrina, Jesús M.
The synthesis of glycosyl-α-amino acids presents a significant challenge due to the need for precise glycosidic linkages connecting carbohydrate moieties to amino acids while maintaining stereo- and regiochemical fidelity. Classical methods relying on ionic intermediates (2e–) often involve intricate synthetic procedures, particularly when dealing with 2-N-acetamido-2-deoxyglycosides linked to α-amino acids—a crucial class of glycoconjugates that play important biological roles. Considering the growing prominence of photocatalysis, this study explores various photoredox catalytic approaches to achieving glycosylation reactions. Our focus lies on the notoriously difficult case of 2-N-acetamido-2-deoxyglycosyl-α-amino acids, which could be obtained efficiently by two methodologies that involved, on the one hand, photoredox Giese reactions using a chiral dehydroalanine (Dha) as an electron density-deficient alkene in these radical 1,4-additions and, on the other hand, photoredox glycosylations using selenoglycosides as glycosyl donors and hydroxyl groups of protected amino acids as acceptors., We thank the Agencia Estatal de Investigación of Spain (AEI; PID2021-127622OB-I00 and PDC2022-133725-C21 projects), the Asociación Española Contra el Cáncer (AECC, INNOVA project 2023), Universidad de La Rioja (REGI22/47 and REGI22/16 projects), and the EU (Marie-Sklodowska Curie ITN, DIRNANO, grant agreement No. 956544). C.B. and M.T. thank (AECC La Rioja) for predoctoral fellowships., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Structural and mechanistic insights into the cleavage of clustered O-glycan patches-containing glycoproteins by mucinases of the human gut

  • Taleb, Víctor
  • Liao, Qinghua
  • Narimatsu, Yoshiki
  • García-García, Ana
  • Compañón, Ismael
  • Junqueira Borges, Rafael
  • González-Ramírez, Andrés Manuel
  • Corzana, Francisco
  • Clausen, Henrik
  • Rovira, Carme
  • Hurtado-Guerrero, Ramon
Mucinases of human gut bacteria cleave peptide bonds in mucins strictly depending on the presence of neighboring O-glycans. The Akkermansia muciniphila AM0627 mucinase cleaves specifically in between contiguous (bis) O-glycans of defined truncated structures, suggesting that this enzyme may recognize clustered O-glycan patches. Here, we report the structure and molecular mechanism of AM0627 in complex with a glycopeptide containing a bis-T (Galβ1-3GalNAcα1-O-Ser/Thr) O-glycan, revealing that AM0627 recognizes both the sugar moieties and the peptide sequence. AM0627 exhibits preference for bis-T over bis-Tn (GalNAcα1-O-Ser/Thr) O-glycopeptide substrates, with the first GalNAc residue being essential for cleavage. AM0627 follows a mechanism relying on a nucleophilic water molecule and a catalytic base Glu residue. Structural comparison among mucinases identifies a conserved Tyr engaged in sugar-π interactions in both AM0627 and the Bacteroides thetaiotaomicron BT4244 mucinase as responsible for the common activity of these two mucinases with bis-T/Tn substrates. Our work illustrates how mucinases through tremendous flexibility adapt to the diversity in distribution and patterns of O-glycans on mucins.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Atomic and specificity details of Mucin 1 O-Glycosylation process by Multiple Polypeptide GalNAc-Transferase Isoforms unveiled by NMR and Molecular Modeling

  • Coelho, Helena
  • Rivas, Matilde de las
  • Grosso, Ana S.
  • Diniz, Ana
  • Soares, Cátia O.
  • Francisco, Rodrigo A.
  • Dias, Jorge S.
  • Compañon, Ismael
  • Sun, Lingbo
  • Narimatsu, Yoshiki
  • Vakhrushev, Sergey Y.
  • Clausen, Henrik
  • Cabrita, Eurico J.
  • Jiménez-Barbero, Jesús
  • Corzana, Francisco
  • Hurtado-Guerrero, Ramon
  • Marcelo, Filipa
The large family of polypeptide GalNAc-transferases (GalNAc-Ts) controls with precision how GalNAc O-glycans are added in the tandem repeat regions of mucins (e.g., MUC1). However, the structural features behind the creation of well-defined and clustered patterns of O-glycans in mucins are poorly understood. In this context, herein, we disclose the full process of MUC1 O-glycosylation by GalNAc-T2/T3/T4 isoforms by NMR spectroscopy assisted by molecular modeling protocols. By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue. In a glycosylated substrate, with yet multiple acceptor sites, the lectin domain contributes to orientate acceptor sites to the catalytic domain. Our experiments suggest that during this process, neighboring tandem repeats are critical for further glycosylation of acceptor sites by GalNAc-T2/T4 in a lectin-assisted manner. Our studies also show local conformational changes in the peptide backbone during incorporation of GalNAc residues, which might explain GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate. Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region. In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope. Finally, the NMR methodology established herein can be extended to other glycosyltransferases, such as C1GalT1 and ST6GalNAc-I, to determine the specificity toward complex mucin acceptor substrates.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Molecular recognition of GalNAc in mucin-type o-glycosylation

  • Sanz-Martinez, I.
  • Pereira, S.
  • Merino, P.
  • Corzana, F.
  • Hurtado-Guerrero, R.
N-Acetylgalactosamine (GalNAc)-type O-glycosylation is an essential posttranslational modification (PTM) that plays fundamental roles in biology. Malfunction of this PTM is exemplified by the presence of truncated O-glycans in cancer. For instance, the glycoprotein MUC1 is overexpressed in many tumor tissues and tends to carry simple oligosaccharides that allow for the presentation of different tumor-associated antigens, such as the Tn or sTn antigens (GalNAc-α-1-O-Thr/Ser and Neu5Acα2-6GalNAcα1-O-Ser/Thr, respectively). In other cases, such as tumoral calcinosis associated with O-glycosylation of the fibroblast growth factor 23, O-glycans are absent or less abundant. Significant progress has been made in determining the three-dimensional structures of biomolecules that recognize GalNAc, such as antibodies, lectins, mucinases, GalNAc-transferases, and other glycosyltransferases. Analysis of the complexes between these entities and GalNAc-containing glycopeptides, in most cases derived from crystallographic or NMR analysis, provides an understanding of the key structural elements that control molecular recognition of these glycopeptides. Here, we describe and compare the binding sites of these proteins in detail, focusing on how the GalNAc moieties interact selectively with them. We also summarize the differences and similarities in GalNAc recognition. In general, the recognition of GalNAc-containing glycopeptides is determined by hydrogen bonds between hydroxyl groups and the N-acetyl group of GalNAc with proteins, as well as CH-π contacts in which the hydrophobic α-face of the sugar and the methyl group of NHAc can be involved. The latter interaction usually provides the basis for selectivity. It is worth noting that binding of these glycopeptides depends primarily on recognition of the sugar moiety, with some exceptions such as a few anti-MUC1 antibodies that primarily recognize the peptide backbone and use the sugar to facilitate shape complementarity or to establish a limited number of interactions with the protein. Focusing specifically on the GalNAc moiety, we can observe that there is some degeneracy of interactions within the same protein families, likely due to substrate flexibility. However, when all studied proteins are considered together, despite the commonalities within each protein family, no pattern can be discerned between the different families, apart from the presence of common residues such as Tyr, His, or Asp, which are responsible for hydrogen bonds. The lack of a pattern can be anticipated, given the diverse functions of mucinases, glycosyltransferases, antibodies, and lectins. Finally, it is important to point out that the conformational differences observed in solution in glycopeptides bearing GalNAc-α-1-O-Ser or GalNAc-α-1-O-Thr also can be found in the bound state. This unique characteristic is exploited, for instance, by the enzyme C1GalT1 to broadly glycosylate both acceptor substrates. The findings summarized in this review may contribute to the rational structure-guided development of therapeutic vaccines, novel diagnostic tools for early cancer detection, and new cancer treatments for cancer with tailored anti-Tn or anti-STn antibodies or new drugs to inhibit GalNAc-T isoenzymes.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Structure-Guided Approach for the Development of MUC1-Glycopeptide-Based Cancer Vaccines with Predictable Responses

  • Bermejo, Iris A.
  • Guerreiro, Ana
  • Eguskiza, Ander
  • Martínez-Sáez, Nuria
  • Lazaris, Foivos S.
  • Asín, Alicia
  • Somovilla, Víctor J.
  • Compañón, Ismael
  • Raju, Tom K.
  • Tadic, Srdan
  • Garrido, Pablo
  • García-Sanmartín, Josune
  • Mangini, Vincenzo
  • Grosso, Ana S.
  • Marcelo, Filipa
  • Avenoza, Alberto
  • Busto, Jesús H.
  • García-Martín, Fayna
  • Hurtado-Guerrero, Ramón
  • Peregrina, Jesús M.
  • Bernardes, Gonçalo J. L.
  • Martínez, Alfredo
  • Fiammengo, Roberto
  • Corzana, Francisco
Mucin-1 (MUC1) glycopeptides are exceptional candidates for potential cancer vaccines. However, their autoantigenic nature often results in a weak immune response. To overcome this drawback, we carefully engineered synthetic antigens with precise chemical modifications. To be effective and stimulate an anti-MUC1 response, artificial antigens must mimic the conformational dynamics of natural antigens in solution and have an equivalent or higher binding affinity to anti-MUC1 antibodies than their natural counterparts. As a proof of concept, we have developed a glycopeptide that contains noncanonical amino acid (2S,3R)-3-hydroxynorvaline. The unnatural antigen fulfills these two properties and effectively mimics the threonine-derived antigen. On the one hand, conformational analysis in water shows that this surrogate explores a landscape similar to that of the natural variant. On the other hand, the presence of an additional methylene group in the side chain of this analog compared to the threonine residue enhances a CH/π interaction in the antigen/antibody complex. Despite an enthalpy–entropy balance, this synthetic glycopeptide has a binding affinity slightly higher than that of its natural counterpart. When conjugated with gold nanoparticles, the vaccine candidate stimulates the formation of specific anti-MUC1 IgG antibodies in mice and shows efficacy comparable to that of the natural derivative. The antibodies also exhibit cross-reactivity to selectively target, for example, human breast cancer cells. This investigation relied on numerous analytical (e.g., NMR spectroscopy and X-ray crystallography) and biophysical techniques and molecular dynamics simulations to characterize the antigen–antibody interactions. This workflow streamlines the synthetic process, saves time, and reduces the need for extensive, animal-intensive immunization procedures. These advances underscore the promise of structure-based rational design in the advance of cancer vaccine development.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Detection of tumor-associated autoantibodies in the sera of pancreatic cancer patients using engineered muc1 glycopeptide nanoparticle probes

  • Corzana, Francisco
  • Asín, Alicia
  • Eguskiza, Ander
  • De Tomi, Elisa
  • Martín-Carnicero, Alfonso
  • Martínez-Moral, María P.
  • Mangini, Vincenzo
  • Papi, Francesco
  • Bretón, Carmen
  • Oroz, Paula
  • Lagartera, Laura
  • Jiménez-Moreno, Ester
  • Avenoza, Alberto
  • Busto, Jesús H.
  • Nativi, Cristina
  • Asensio, Juan L.
  • Hurtado-Guerrero, Ramón
  • Peregrina, Jesús M.
  • Malerba, Giovanni
  • Martínez, Alfredo
  • Fiammengo, Roberto
Pancreatic cancer is one of the deadliest cancers worldwide, mainly due to late diagnosis. Therefore, there is an urgent need for novel diagnostic approaches to identify the disease as early as possible. We have developed a diagnostic assay for pancreatic cancer based on the detection of naturally occurring tumor associated autoantibodies against Mucin‐1 (MUC1) using engineered glycopeptides on nanoparticle probes. We used a structure‐guided approach to develop unnatural glycopeptides as model antigens for tumor‐associated MUC1. We designed a collection of 13 glycopeptides to bind either SM3 or 5E5, two monoclonal antibodies with distinct epitopes known to recognize tumor associated MUC1. Glycopeptide binding to SM3 or 5E5 was confirmed by surface plasmon resonance and rationalized by molecular dynamics simulations. These model antigens were conjugated to gold nanoparticles and used in a dot‐blot assay to detect autoantibodies in serum samples from pancreatic cancer patients and healthy volunteers. Nanoparticle probes with glycopeptides displaying the SM3 epitope did not have diagnostic potential. Instead, nanoparticle probes displaying glycopeptides with high affinity for 5E5 could discriminate between cancer patients and healthy controls. Remarkably, the best‐discriminating probes show significantly better true and false positive rates than the current clinical biomarkers CA19‐9 and carcinoembryonic antigen (CEA).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Exploring Photoredox Catalytic Reactions as an Entry to Glycosyl-a-amino Acids

  • Bretón, Carmen
  • Oroz, Paula
  • Torres, Miguel
  • Zurbano, María M.
  • García-Orduña, Pilar
  • Avenoza, Alberto
  • Busto, Jesús H.
  • Corzana, Francisco
  • Peregrina, Jesús M.
The synthesis of glycosyl-α-amino acids presents a significant challenge due to the need for precise glycosidic linkages connecting carbohydrate moieties to amino acids while maintaining stereo- and regiochemical fidelity. Classical methods relying on ionic intermediates (2e–) often involve intricate synthetic procedures, particularly when dealing with 2-N-acetamido-2-deoxyglycosides linked to α-amino acids─a crucial class of glycoconjugates that play important biological roles. Considering the growing prominence of photocatalysis, this study explores various photoredox catalytic approaches to achieving glycosylation reactions. Our focus lies on the notoriously difficult case of 2-N-acetamido-2-deoxyglycosyl-α-amino acids, which could be obtained efficiently by two methodologies that involved, on the one hand, photoredox Giese reactions using a chiral dehydroalanine (Dha) as an electron density-deficient alkene in these radical 1,4-additions and, on the other hand, photoredox glycosylations using selenoglycosides as glycosyl donors and hydroxyl groups of protected amino acids as acceptors.